AbbVie (NYSE:ABBV) Stock: Insider Jeffrey Ryan Stewart Sells 40,619 Shares

AbbVie Inc. (NYSE:ABBV) EVP Jeffrey Stewart sold 40,619 shares of the firm’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the sale, the executive vice president owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. This represents a 32.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

AbbVie Stock Performance

Shares of ABBV stock opened at $295.18 on Friday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $302.93. The company has a market capitalization of $521.76 billion, a price-to-earnings ratio of 50.81, a PEG ratio of 1.34 and a beta of 0.20. The company has a 50-day simple moving average of $275.51 and a 200 day simple moving average of $240.91.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating the consensus estimate of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The firm had revenue of $17.40 billion for the quarter, compared to analysts’ expectations of $17.32 billion. During the same period in the prior year, the firm earned $1.86 EPS. The business’s revenue was up 10.3% on a year-over-year basis. Sell-side analysts forecast that AbbVie Inc. will post 13.98 EPS for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be given a dividend of $1.82 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Friday, January 15th. AbbVie’s dividend payout ratio (DPR) is currently 125.30%.

AbbVie News Summary

Investors following ABBV have been watching these news items:

• Positive Sentiment: AbbVie reported positive Phase 3 results for QULIPTA in a migraine trial, a potential boost to its neuroscience portfolio and the drug’s growth prospects. AbbVie Reports Positive Phase 3 QULIPTA Migraine Trial Results
• Positive Sentiment: AbbVie’s immunology sales grew 16.6% in the third quarter, led by Skyrizi and Rinvoq. Their momentum is helping lift sales expectations for 2026, although Humira continues to decline. How Did AbbVie’s Immunology Franchise Fare in Q3?
• Negative Sentiment: EVP Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. The sale could weigh on sentiment, though the filing did not state a reason. AbbVie EVP Sells $11,925,738.40 in Stock

Hedge Funds Weigh In On AbbVie

Institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp raised its position in shares of AbbVie by 0.3% during the third quarter. State Street Corp now owns 82,815,387 shares of the company’s stock worth $21,663,677,000 after acquiring an additional 218,639 shares during the last quarter. Fisher Asset Management LLC grew its stake in AbbVie by 252.6% during the third quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock worth $8,760,498,000 after purchasing an additional 23,991,451 shares during the period. Corient Private Wealth LP bought a new stake in shares of AbbVie in the 2nd quarter valued at $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of AbbVie by 0.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after purchasing an additional 106,091 shares in the last quarter. Finally, Legal & General Group Plc bought a new position in AbbVie in the second quarter worth approximately $2,905,952,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

ABBV has been the subject of several analyst reports. HSBC boosted their target price on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Bank of America restated a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Weiss Ratings upgraded AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Canaccord Genuity Group boosted their price target on AbbVie from $290.00 to $338.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. Finally, Royal Bank Of Canada upped their price objective on AbbVie from $280.00 to $330.00 and gave the stock an “outperform” rating in a research report on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $297.46.

About AbbVie

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.